Lakshmi Sukumaran1, Natalie L McCarthy2, Rongxia Li2, Eric S Weintraub2, Steven J Jacobsen3, Simon J Hambidge4, Lisa A Jackson5, Allison L Naleway6, Berwick Chan7, Biwen Tao2, Julianne Gee2. 1. Immunization Safety Office, Centers for Disease Control and Prevention, Atlanta, Georgia; Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia. Electronic address: xfq3@cdc.gov. 2. Immunization Safety Office, Centers for Disease Control and Prevention, Atlanta, Georgia. 3. Department of Research and Evaluation, Kaiser Permanente of Southern California, Pasadena, California, USA. 4. Department of Ambulatory Care Services, Denver Health, Institute for Health Research, Kaiser Permanente Colorado, Department of Pediatrics, University of Colorado, Denver, Colorado, USA. 5. Group Health Research Institute, Seattle, Washington, USA. 6. The Center for Health Research, Kaiser Permanente Northwest, Portland, Oregon, USA. 7. Kaiser Permanente Vaccine Study Center, Oakland, California, USA.
Abstract
BACKGROUND: The Vaccine Safety Datalink (VSD) is a collaboration between CDC and nine integrated health care systems that serves as a cornerstone of US post-licensure vaccine safety monitoring. Given concerns that potential differences between the insured VSD population and the US population could limit the generalizability of VSD study findings, we performed a comparison of the demographic characteristics between the two populations. METHODS: We collected data from medical records and administrative files at VSD sites in 2010 to compare sex, age, race, ethnicity, income, and educational attainment to the 2010 US Census population. We also compared data on the 2012 VSD Medicaid population to 2012 US Medicaid data. RESULTS: The VSD population included over eight million individuals in 2010, which represented 2.6% of the total US population. All major demographic groups were represented in the VSD. We found no major differences in comparing sex, race, ethnicity, and educational attainment between the VSD and the US population. Middle income populations were comparable between the VSD and the US. While the percentage of lower income populations was less in the VSD compared to the US, the VSD had over two million individuals in this group. Additionally, there were over 600,000 Medicaid members in the VSD in 2012, which represented 1.1% of the US Medicaid population. CONCLUSIONS: We found that the VSD population is representative of the general US population on several key demographic and socioeconomic variables. Despite a few specific groups being underrepresented in the VSD compared to the US, the absolute number of VSD members is large enough to ensure significant representation of these groups in vaccine safety studies that use VSD data.
BACKGROUND: The Vaccine Safety Datalink (VSD) is a collaboration between CDC and nine integrated health care systems that serves as a cornerstone of US post-licensure vaccine safety monitoring. Given concerns that potential differences between the insured VSD population and the US population could limit the generalizability of VSD study findings, we performed a comparison of the demographic characteristics between the two populations. METHODS: We collected data from medical records and administrative files at VSD sites in 2010 to compare sex, age, race, ethnicity, income, and educational attainment to the 2010 US Census population. We also compared data on the 2012 VSD Medicaid population to 2012 US Medicaid data. RESULTS: The VSD population included over eight million individuals in 2010, which represented 2.6% of the total US population. All major demographic groups were represented in the VSD. We found no major differences in comparing sex, race, ethnicity, and educational attainment between the VSD and the US population. Middle income populations were comparable between the VSD and the US. While the percentage of lower income populations was less in the VSD compared to the US, the VSD had over two million individuals in this group. Additionally, there were over 600,000 Medicaid members in the VSD in 2012, which represented 1.1% of the US Medicaid population. CONCLUSIONS: We found that the VSD population is representative of the general US population on several key demographic and socioeconomic variables. Despite a few specific groups being underrepresented in the VSD compared to the US, the absolute number of VSD members is large enough to ensure significant representation of these groups in vaccine safety studies that use VSD data.
Authors: William W Thompson; Cristofer Price; Barbara Goodson; David K Shay; Patti Benson; Virginia L Hinrichsen; Edwin Lewis; Eileen Eriksen; Paula Ray; S Michael Marcy; John Dunn; Lisa A Jackson; Tracy A Lieu; Steve Black; Gerrie Stewart; Eric S Weintraub; Robert L Davis; Frank DeStefano Journal: N Engl J Med Date: 2007-09-27 Impact factor: 91.245
Authors: Thomas Verstraeten; Robert L Davis; Frank DeStefano; Tracy A Lieu; Philip H Rhodes; Steven B Black; Henry Shinefield; Robert T Chen Journal: Pediatrics Date: 2003-11 Impact factor: 7.124
Authors: Eric S Weintraub; James Baggs; Jonathan Duffy; Claudia Vellozzi; Edward A Belongia; Stephanie Irving; Nicola P Klein; Jason M Glanz; Steven J Jacobsen; Allison Naleway; Lisa A Jackson; Frank DeStefano Journal: N Engl J Med Date: 2014-01-14 Impact factor: 91.245
Authors: Michael M McNeil; Julianne Gee; Eric S Weintraub; Edward A Belongia; Grace M Lee; Jason M Glanz; James D Nordin; Nicola P Klein; Roger Baxter; Allison L Naleway; Lisa A Jackson; Saad B Omer; Steven J Jacobsen; Frank DeStefano Journal: Vaccine Date: 2014-08-06 Impact factor: 3.641
Authors: Elyse O Kharbanda; Gabriela Vazquez-Benitez; Heather S Lipkind; Nicola P Klein; T Craig Cheetham; Allison Naleway; Saad B Omer; Simon J Hambidge; Grace M Lee; Michael L Jackson; Natalie L McCarthy; Frank DeStefano; James D Nordin Journal: JAMA Date: 2014-11-12 Impact factor: 56.272
Authors: Feifei Wei; John P Mullooly; Mike Goodman; Maribet C McCarty; Ann M Hanson; Bradley Crane; James D Nordin Journal: BMC Pediatr Date: 2009-03-05 Impact factor: 2.125
Authors: Lina S Sy; Kristin I Meyer; Nicola P Klein; Chun Chao; Christine Velicer; T Craig Cheetham; Bradley K Ackerson; Jeff M Slezak; Harpreet S Takhar; John Hansen; Kamala Deosaransingh; Kai-Li Liaw; Steven J Jacobsen Journal: Hum Vaccin Immunother Date: 2017-12-14 Impact factor: 3.452
Authors: Matthew F Daley; Christina L Clarke; Jason M Glanz; Stanley Xu; Simon J Hambidge; James G Donahue; James D Nordin; Nicola P Klein; Steven J Jacobsen; Allison L Naleway; Michael L Jackson; Grace Lee; Jonathan Duffy; Eric Weintraub Journal: Pharmacoepidemiol Drug Saf Date: 2017-11-17 Impact factor: 2.890
Authors: Rulin C Hechter; Lei Qian; Sara Y Tartof; Lina S Sy; Nicola P Klein; Eric Weintraub; Cheryl Mercado; Allison Naleway; Huong Q McLean; Steven J Jacobsen Journal: Vaccine Date: 2019-05-04 Impact factor: 3.641
Authors: Matthew F Daley; Jason M Glanz; Sophia R Newcomer; Michael L Jackson; Holly C Groom; Marlene M Lugg; Huong Q McLean; Nicola P Klein; Eric S Weintraub; Michael M McNeil Journal: Vaccine Date: 2017-03-09 Impact factor: 3.641
Authors: Ousseny Zerbo; Sharareh Modaressi; Kristin Goddard; Edwin Lewis; Bruce H Fireman; Matthew F Daley; Stephanie A Irving; Lisa A Jackson; James G Donahue; Lei Qian; Darios Getahun; Frank DeStefano; Michael M McNeil; Nicola P Klein Journal: JAMA Pediatr Date: 2018-05-01 Impact factor: 16.193
Authors: Matthew F Daley; Jo Ann Shoup; Sophia R Newcomer; Michael L Jackson; Holly C Groom; Steven J Jacobsen; Huong Q McLean; Nicola P Klein; Eric S Weintraub; Michael M McNeil; Jason M Glanz Journal: Acad Pediatr Date: 2018-03-28 Impact factor: 3.107
Authors: Bobbi Jo H Yarborough; Nancy A Perrin; Scott P Stumbo; John Muench; Carla A Green Journal: Am J Prev Med Date: 2017-10-19 Impact factor: 5.043
Authors: Lakshmi Sukumaran; Natalie L McCarthy; Elyse O Kharbanda; Michael M McNeil; Allison L Naleway; Nicola P Klein; Michael L Jackson; Simon J Hambidge; Marlene M Lugg; Rongxia Li; Eric S Weintraub; Robert A Bednarczyk; Jennifer P King; Frank DeStefano; Walter A Orenstein; Saad B Omer Journal: JAMA Date: 2015-10-20 Impact factor: 56.272